ArticleRedox biology2026
Maternal hyperhomocysteinemia promotes adverse pregnancy outcomes via mtDNA-cGAS-STING signaling-mediated trophoblast mitophagy.
Article in Redox biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesHyperhomocysteinemia (HHcy) is a recognized risk factor for adverse pregnancy outcomes. However, the underlying mechanisms precipitating placental dysfunction, particularly the potential involvement of mitochondrial DNA (mtDNA), remain largely elusive. This study aims to investigate the association between maternal HHcy and adverse pregnancy outcomes mediated by reduced placental mtDNA copy number (mtDNAcn), and to elucidate the underlying molecular mechanisms driving HHcy-induced placental dysfunction.
methodsWe prospectively investigated the associations between maternal HHcy, placental mtDNA copy number (mtDNAcn), and adverse pregnancy outcomes using data from the PEOH (Prenatal Environments and Offspring Health) birth cohort. To elucidate the underlying mechanisms, human placental tissues, maternal HHcy rat placentae, and HTR-8/SVneo trophoblast cells were utilized to assess HHcy-induced mitochondrial damage, PINK1/Parkin-mediated mitophagy, and downstream inflammatory signaling.
resultsEpidemiological analysis revealed that maternal HHcy was significantly associated with increased risks of preterm birth and low birth weight, with reduced placental mtDNAcn serving as a critical mediator. Mechanistically, HHcy exposure induced severe mitochondrial dysfunction and excessive PINK1/Parkin-dependent mitophagy across human placentae, maternal HHcy rat placentae, and HTR-8/SVneo cells. This unrestrained mitophagic flux precipitated the leakage of mtDNA into the cytosol, which directly engaged and activated the cGAS-STING pathway, leading to placental sterile inflammation and subsequent placental dysfunction via upregulating COX-2 and pro-inflammatory cytokines.
conclusionMaternal HHcy exposure contributes to adverse pregnancy outcomes by reducing placental mtDNAcn and triggering a cascade of PINK1/Parkin-mediated mitophagic disruption, cytosolic mtDNA release, and subsequent cGAS-STING-driven sterile inflammation and placental dysfunction, underscoring the need for clinical Hcy monitoring and early intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.